Lin Shen
Tracked across 1 events · 6 articles · First seen Jul 02, 2026 · Last active Jul 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Professor Lin Shen, a leading Principal Investigator, highlighted the significance of ORPATHYS (savolitinib) approval for biomarker-driven precision medicine in gastrointestinal oncology.
Jul 02, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Lin Shen live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard